Pharmafile Logo

Gazyva

- PMLiVE

Merck & Co’s Keytruda muscles further ahead of rivals in lung cancer

Granted accelerated review by FDA for use in combination with chemotherapy

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

Roche Basel Switzerland

Roche’s haemophilia A drug hits targets in registration trial

Emicizumab from Japanese affiliate Chugai cleared a phase III trial

Roche Basel Switzerland

FDA delays verdict on Roche’s MS drug Ocrevus

Additional manufacturing data postpones US verdict until 28 March 2017

Roche Basel Switzerland

Genentech names Anderson new CEO as Ian Clark retires

Leadership changes come as the Roche subsidiary faces increasing biologics competition

- PMLiVE

Novartis’ AMD drug pegpleranib fails phase III programme

Plans for Lucentis-boosting duel-therapy stumble as trial data show no additional benefit

- PMLiVE

Pfizer’s SMO inhibitor boosts survival in blood cancer trial

Glasdegib first to show benefit in patients with AML or MDS

Roche's Perjeta pertuzumab

NICE backs Roche’s Perjeta for routine NHS use

Set to become first new breast cancer drug in nine years after discount agreed

- PMLiVE

Boehringer says Avastin biosimilar on track as Phase III gets underway

Clinical data suggests candidate has same biologic profile as Roche’s cancer drug

Novartis building

Novartis gets speedy FDA review for midostaurin

Leukaemia treatment could become first targeted therapy for 25 years

Sanofi reception

Manufacturing issues scupper Sanofi’s sarilumab launch plans

FDA turns down the rheumatoid arthritis drug’s marketing application after routine inspection

- PMLiVE

Merck gets early OK for Keytruda in first-line lung cancer

FDA fast-tracks approval of PD-1/PD-L1 inhibitor for treatment of NSCLC

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links